Riskpilot← Back to searchSign inGet full accessBeactica Therapeutics AB
ABActiveOrg 5567082853Rapsgatan 7 Uppsala BuisnessparkResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20061-4 employees
Revenue 2024
SEK 8,7M
+18% vs 2023
EBITDA margin
-56.3%
+44% vs 2023
Equity ratio
92.7%
Financial strength
Net profit 2024
SEK -4,9M
+46% vs 2023
| Revenue | SEK 8,7M | +18% |
| EBITDA | SEK -4,9M | +44% |
| Net profit | SEK -4,9M | +46% |
| Total assets | SEK 32,2M | +7% |
| Equity | SEK 29,8M | +10% |
| Employees | — | — |
Legal name
Beactica Therapeutics AB
Org number
5567082853
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11 augusti 2006
Share capital
SEK 388 315
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhet skall vara att utveckla nya metoder och strategier för läkemedelsutveckling, samt annan därmed förenlig verksamhet.
Address
Rapsgatan 7 Uppsala Buisnesspark
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 941 | 4 469 | 7 341 | 7 385 | 8 701 |
| Staff expenses | — | — | — | — | −6 678 |
| EBITDA | −11 390 | −9 520 | −10 340 | −8 742 | −4 901 |
| Depreciation & amort. | −1 547 | −536 | −203 | −180 | −46 |
| EBIT | −12 937 | −10 056 | −10 543 | −8 922 | −4 947 |
| Net financials | −195 | −142 | −109 | −97 | 33 |
| Profit before tax | −13 133 | −10 199 | −10 652 | −9 019 | −4 914 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −13 133 | −10 199 | −10 652 | −9 019 | −4 914 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 28 804 | 28 343 | 36 506 | 29 972 | 32 175 |
| Equity | 21 730 | 21 699 | 31 135 | 27 118 | 29 813 |
| Long-term debt | 2 742 | 1 798 | 1 049 | 486 | 0 |
| Short-term debt | 4 331 | 4 846 | 4 323 | 2 368 | 2 362 |
| Total debt | 7 073 | 6 644 | 5 372 | 2 854 | 2 362 |
EBITDA margin
-56.3%
This company
15.8%
Market median
-456% vs market
20202024
Equity ratio
92.7%
This company
38.2%
Market median
+143% vs market
20202024
Return on equity
-16.5%
This company
18.4%
Market median
-190% vs market
20202024
Net profit margin
-56.5%
This company
8.1%
Market median
-798% vs market
20202024
Asset turnover
0.27×
This company
1.12×
Market median
-76% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MK | Audit | 2021 |
PK Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2021 | |
| Chairman | 2022 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Former (3) | ||
| Board of Directors | 2021 – 2024 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Beactica Therapeutics AB (this company)
Beactica Therapeutics Uk LimitedBEACTICA THERAPEUTICS UK LIMITEDBoard members of Beactica Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Kristina Wigenfeldt | Audit | 0 companies |
| Per Källblad | Chief Executive Officer | 0 companies |
| Erik Johan Lennart Walldén | Board of Directors | 0 companies |
| Gullik Håkan Wickholm | Chairman | 0 companies |
| Jarl Ulf Birger Jungnelius | Board of Directors | 0 companies |
| Gisela Marie Sitbon | Chairman | 0 companies |
| Ted Ingemar Jakob Fjällman | Board of Directors | 0 companies |
| Ulla Helena Danielson | Board of Directors | 0 companies |
| Christina Elisabeth Herder | Board of Directors | 0 companies |
| Maarten De Chateau | Board of Directors | 0 companies |